MY ACCOUNT | NEWSLETTER |

Metallothionein expression in feline injection site fibrosarcomas


Feline injection site fibrosarcoma is an aggressive and infiltrative tumor arising in the background of chronic inflammation. The aim of this study was to evaluate the expression of metallothionein (I-II) in feline injection site fibrosarcomas and to assess its possible relationships with Ki67 index, inflammation score and tumor grade. 

The study included 40 feline fibrosarcomas, located in the common injection sites (i.e., interscapular area, thigh, flank), constituting archival diagnostic specimens collected between 2019 to 2020. Tumors were graded histologically according to the newly proposed soft-tissue sarcoma grading system in cats. 

Immunohistochemistry was performed to evaluate the expression of Ki67 and metallothionein in tumor cells.

The cytoplasmic and sometimes nuclear expression of metallothionein was observed in all tumors grade I, 66.67% of tumors grade II and 55% of tumors grade III. The expression of metallothionein was negatively correlated with tumor grade and inflammation score, while the Ki67 index was positively correlated with tumor grade, inflammation score and necrosis score.

The downregulation of MT expression in feline injection site fibrosarcomas seems to relate to an increase in inflammatory infiltration, leading to tumor progression. In conclusion, the authors said this is the first study describing metallothionein expression in feline injection site fibrosarcomas.

Mateusz Mikiewicz, et al. “Metallothionein expression in feline injection site fibrosarcomas.” BMC Vet Res. 10 February 2023;19(1):42.  doi: 10.1186/s12917-023-03604-5.

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Unlocking the potential of ICT innovation in veterinary healthcare: The pathway to improve practices and business model

Like0
Dislike0

Canine papillomavirus: status of diagnostic methods and vaccine innovations

Like0
Dislike0

Analysing innovations among cattle smallholders to evaluate the adequacy of breeding programs

Like0
Dislike0

40 Under 40: Dr. Cassi Fleming

Like0
Dislike0

CORRECTING and REPLACING Petwealth Emerges from Stealth with $1.7 Million in Funding, Landmark Partnerships, and a Mission to Become the Functional Health Platform for Pets

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top